Summit Therapeutics
Summit Therapeutics Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in the discovery, development, and commercialization of novel antibiotics aimed at treating serious infectious diseases. The company focuses on addressing Clostridium difficile infection (CDI) with its lead product candidate, ridinilazole, which is currently undergoing Phase III clinical trials. Additionally, Summit is developing the DDS-01 series to combat infections caused by Neisseria gonorrhoeae and the DDS-04 series targeting Enterobacteriaceae. With operations in the United States and Europe, Summit Therapeutics aims to establish new standards of care for patients while creating value for payors and healthcare providers. Founded in 2003, the company is committed to advancing innovative treatments for infectious diseases.
Top Stages
2 past transactions
Discuva
Acquisition in 2017
Discuva, based in Cambridge, UK, is a company focused on discovering next-generation antibiotics. Established to tackle gaps in current antibiotic treatments, Discuva employs proprietary methods derived from recent genomic technology advancements. The company aims to develop targeted antibiotics effective against emerging and drug-resistant pathogens, addressing the growing threat of antimicrobial resistance.
DanioLabs
Acquisition in 2007
DanioLabs Ltd. discovers and develops therapeutics for neurological, ophthalmologic, metabolic, and gastrointestinal diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.